{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28Human%29", "query": { "intervention": "Immune Globulin Intravenous (Human)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 461, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28Human%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T00:12:12.913Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04083183", "title": "Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Malignant Neoplasm" ], "interventions": [ { "name": "Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Lapine T-Lymphocyte Immune Globulin", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 40, "start_date": "2020-06-16", "completion_date": "2028-01-09", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083183" }, { "nct_id": "NCT03749096", "title": "Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stiff-Person Syndrome" ], "interventions": [ { "name": "Intravenous Immunoglobulins, Human", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-12-07", "completion_date": "2019-04-26", "has_results": false, "last_update_posted_date": "2019-06-13", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03749096" }, { "nct_id": "NCT00110708", "title": "Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism", "Autistic Disorder", "Child Development Disorders, Pervasive", "Gastrointestinal Diseases", "Signs and Symptoms, Digestive" ], "interventions": [ { "name": "Oralgam (human immunoglobulin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PediaMed Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 120, "start_date": "2005-04", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2006-02-22", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110708" }, { "nct_id": "NCT03689699", "title": "Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Adenocarcinoma of the Prostate" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Degarelix", "type": "DRUG" }, { "name": "BMS-986253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mark Stein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 59, "start_date": "2018-10-11", "completion_date": "2026-01", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03689699" }, { "nct_id": "NCT06752356", "title": "A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Inflammatory Demyelinating Polyneuropathy" ], "interventions": [ { "name": "Immune globulin (human) 10% solution for intravenous administration", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kedrion S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2026-10", "completion_date": "2027-12-27", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 5, "location_summary": "Stamford, Connecticut • Miami, Florida • Tampa, Florida + 2 more", "locations": [ { "city": "Stamford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06752356" }, { "nct_id": "NCT00930683", "title": "A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Scleroderma" ], "interventions": [ { "name": "MEDI-546", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2009-09", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2012-05-08", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 11, "location_summary": "Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00930683" }, { "nct_id": "NCT01628055", "title": "IVIG in Acute Ischemic Stroke: A Pilot Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ischemic Stroke" ], "interventions": [ { "name": "Privigen", "type": "BIOLOGICAL" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "45 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2013-03", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2013-11-11", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 1, "location_summary": "Falls Church, Virginia", "locations": [ { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01628055" }, { "nct_id": "NCT07169734", "title": "A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Squamous Cell Carcinoma", "Squamous Non-small-cell Lung Cancer", "Colorectal Cancer", "Intrahepatic Cholangiocarcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "ALE.P03", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alentis Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-08-26", "completion_date": "2029-10-04", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07169734" }, { "nct_id": "NCT00622609", "title": "Anti-MAG First Administration to Human", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cerebrovascular Accident" ], "interventions": [ { "name": "GSK249320A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 46, "start_date": "2007-08-01", "completion_date": "2009-04-09", "has_results": false, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00622609" }, { "nct_id": "NCT00671372", "title": "A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "dulanermin", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2006-07", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-04T00:12:12.913Z", "location_count": 10, "location_summary": "Los Angeles, California • Redlands, California • San Francisco, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671372" } ] }